CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression

Nucleic Acids Research

Volumn 45, Issue 9, 2017, Pages 5153-5169

  Zaghloul, Eman M ^a,b   Gissberg, Olof ^a   Moreno, Pedro M D ^a,c   Siggens, Lee ^a   Hallbrink, Mattias ^d   Jørgensen, Anna S ^e   Ekwall, Karl ^a   Zain, Rula ^a,f   Wengel, Jesper ^e   Lundin, Karin E ^a   Smith, C I Edvard ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Alexandria University Faculty of Pharmacy   (Egypt)

^c UNIVERSITY OF PORTO   (Portugal)

^d STOCKHOLM UNIVERSITY   (Sweden)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PENETRATING PEPTIDE; HUNTINGTIN; MESSENGER RNA; OLIGONUCLEOTIDE; PROTEIN; RNA POLYMERASE II; DNA; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PEPTIDE; PHOSPHOSERINE;

ALLELE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; CTG REPEAT; DOWN REGULATION; DRUG BINDING; DRUG DELIVERY SYSTEM; ENZYME ASSAY; FIBROBLAST; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HTT GENE; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; NUCLEIC ACID STRUCTURE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRINUCLEOTIDE REPEAT; ULTRAVIOLET SPECTROPHOTOMETRY; DNA DENATURATION; DRUG EFFECTS; GENETICS; METABOLISM; PHOSPHORYLATION; RESTRICTION MAPPING; ULTRAVIOLET RADIATION;

ALLELES; DNA; DOWN-REGULATION; FIBROBLASTS; GENE KNOCKDOWN TECHNIQUES; HUMANS; HUNTINGTIN PROTEIN; NUCLEIC ACID DENATURATION; PEPTIDES; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; PHOSPHORYLATION; PHOSPHOSERINE; RESTRICTION MAPPING; RNA POLYMERASE II; RNA, MESSENGER; TRINUCLEOTIDE REPEAT EXPANSION; ULTRAVIOLET RAYS;

EID: 85027122602     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkx111     Document Type: Article

References (78)

1. Snowden,J.S., Craufurd,D., Thompson,J. and Neary,D. (2002) Psychomotor, executive, and memory function in preclinical Huntington's disease. J. Clin. Exp. Neuropsychol., 24, 133-145.
2. Simpson,S.A. (2007) Late stage care in Huntington's disease. Brain Res. Bull., 72, 179-181.
3. MacDonald,M.E., Ambrose,C.M., Duyao,M.P., Myers,R.H., Lin,C.S., Srinidhi,L., Barnes,G., Taylor,S.A., James,M., Groat,N. et al. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell, 72, 971-983.
4. Ross,C.A. and Tabrizi,S.J. (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol., 10, 83-98.
5. Pringsheim,T., Wiltshire,K., Day,L., Dykeman,J., Steeves,T. and Jette,N. (2012) The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov. Disord, 27, 1083-1091.
6. Rubinsztein,D.C. and Carmichael,J. (2003) Huntington's disease: molecular basis of neurodegeneration. Expert Rev. Mol. Med., 5, 1-21.
7. Persichetti,F., Carlee,L., Faber,P.W., McNeil,S.M., Ambrose,C.M., Srinidhi,J., Anderson,M., Barnes,G.T., Gusella,J.F. and MacDonald,M.E. (1996) Differential expression of normal and mutant Huntington's disease gene alleles. Neurobiol. Dis., 3, 183-190.
8. Ambrose,C.M., Duyao,M.P., Barnes,G., Bates,G.P., Lin,C.S., Srinidhi,J., Baxendale,S., Hummerich,H., Lehrach,H., Altherr,M. et al. (1994) Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somat. Cell Mol. Genet., 20, 27-38.
9. Zeitlin,S., Liu,J.P., Chapman,D.L., Papaioannou,V.E. and Efstratiadis,A. (1995) Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet., 11, 155-163.
10. Boudreau,R.L., McBride,J.L., Martins,I., Shen,S., Xing,Y., Carter,B.J. and Davidson,B.L. (2009) Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol. Ther., 17, 1053-1063.
11. Grondin,R., Kaytor,M.D., Ai,Y., Nelson,P.T., Thakker,D.R., Heisel,J., Weatherspoon,M.R., Blum,J.L., Burright,E.N., Zhang,Z. et al. (2012) Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain, 135, 1197-1209.
12. Lu,B. and Palacino,J. (2013) A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration. FASEB J., 27, 1820-1829.
13. McBride,J.L., Pitzer,M.R., Boudreau,R.L., Dufour,B., Hobbs,T., Ojeda,S.R. and Davidson,B.L. (2011) Preclinical safety of RNAi-mediated HTT suppression in the Rhesus Macaque as a potential therapy for Huntington's Disease. Mol. Ther., 19, 2152-2162.
14. Banez-Coronel,M., Porta,S., Kagerbauer,B.,Mateu-Huertas,E., Pantano,L., Ferrer,I., Guzman,M., Estivill,X. and Marti,E. (2012) A pathogenic mechanism in Huntington's Disease involves small CAG-repeated RNAs with neurotoxic activity. Plos Genet., 8, e1002481.
15. Rue,L., Banez-Coronel,M., Creus-Muncunill,J., Giralt,A., Alcala-Vida,R.,Mentxaka,G., Kagerbauer,B., Zomeno-Abellan,M.T., Aranda,Z., Venturi,V. et al. (2016) Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels. J. Clin. Invest., 126, 4319-4330.
16. Kay,C., Skotte,N.H., Southwell,A.L. and Hayden,M.R. (2014) Personalized gene silencing therapeutics for Huntington disease. Clin. Genet., 86, 29-36.
17. Fiszer,A. and Krzyzosiak,W.J. (2013) RNA toxicity in polyglutamine disorders: concepts, models, and progress of research. J. Mol. Med., 91, 683-691.
18. de Mezer,M., Wojciechowska,M., Napierala,M., Sobczak,K. and Krzyzosiak,W.J. (2011) Mutant CAG repeats of Huntingtin transcript fold into hairpins, form nuclear foci and are targets for RNA interference. Nucleic Acids Res., 39, 3852-3863.
19. Mykowska,A., Sobczak,K., Wojciechowska,M., Kozlowski,P. and Krzyzosiak,W.J. (2011) CAG repeats mimic CUG repeats in the misregulation of alternative splicing. Nucleic Acids Res., 39, 8938-8951.
20. Krol,J., Fiszer,A., Mykowska,A., Sobczak,K., de Mezer,M. and Krzyzosiak,W.J. (2007) Ribonuclease dicer cleaves triplet repeat hairpins into shorter repeats that silence specific targets. Mol. Cell, 25, 575-586.
21. Galka-Marciniak,P., Urbanek,M.O. and Krzyzosiak,W.J. (2012) Triplet repeats in transcripts: structural insights into RNA toxicity. Biol. Chem., 393, 1299-1315.
22. Harper,S.Q. (2009) Progress and challenges in RNA interference therapy for Huntington disease. Arch. Neurol., 66, 933-938.
23. Evers,M.M., Tran,H.D., Zalachoras,I., Meijer,O.C., den Dunnen,J.T., van Ommen,G.J., Aartsma-Rus,A. and van Roon-Mom,W.M. (2014) Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification. Nucleic Acid Ther., 24, 4-12.
24. Southwell,A.L., Skotte,N.H., Kordasiewicz,H.B., Ostergaard,M.E., Watt,A.T., Carroll,J.B., Doty,C.N., Villanueva,E.B., Petoukhov,E., Vaid,K. et al. (2014) In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Mol. Ther., 22, 2093-2106.
25. Garriga-Canut,M., Agustin-Pavon,C., Herrmann,F., Sanchez,A., Dierssen,M., Fillat,C. and Isalan,M. (2012) Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc. Natl. Acad. Sci. U.S.A., 109, E3136-E3145.
26. Kordasiewicz,H.B., Stanek,L.M., Wancewicz,E.V.,Mazur,C., McAlonis,M.M., Pytel,K.A., Artates,J.W., Weiss,A., Cheng,S.H., Shihabuddin,L.S. et al. (2012) Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron, 74, 1031-1044.
27. Hu,J., Matsui,M., Gagnon,K.T., Schwartz,J.C., Gabillet,S., Arar,K., Wu,J., Bezprozvanny,I. and Corey,D.R. (2009) Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat. Biotechnol., 27, 478-484.
28. Sun,X., Marque,L.O., Cordner,Z., Pruitt,J.L., Bhat,M., Li,P.P., Kannan,G., Ladenheim,E.E., Moran,T.H.,Margolis,R.L. et al. (2014) Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity. Hum. Mol. Genet., 23, 6302-6317.
29. Gagnon,K.T., Pendergraff,H.M., Deleavey,G.F., Swayze,E.E., Potier,P., Randolph,J., Roesch,E.B., Chattopadhyaya,J., Damha,M.J., Bennett,C.F. et al. (2010) Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry, 49, 10166-10178.
30. Ostergaard,M.E., Kumar,P., Nichols,J., Watt,A., Sharma,P.K., Nielsen,P. and Seth,P.P. (2015) Allele-selective inhibition of mutant Huntingtin with 2-Thio-and C5-Triazolylphenyl-Deoxythymidine-modified antisense oligonucleotides. Nucleic Acid Ther., 25, 266-274.
31. Yu,D., Pendergraff,H., Liu,J., Kordasiewicz,H.B., Cleveland,D.W., Swayze,E.E., Lima,W.F., Crooke,S.T., Prakash,T.P. and Corey,D.R. (2012) Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell, 150, 895-908.
32. Hu,J., Liu,J., Yu,D., Aiba,Y., Lee,S., Pendergraff,H., Boubaker,J., Artates,J.W., Lagier-Tourenne,C., Lima,W.F. et al. (2014) Exploring the effect of sequence length and composition on allele-selective inhibition of human huntingtin expression by single-stranded silencing RNAs. Nucleic Acid Ther., 24, 199-209.
33. Hu,J., Liu,J. and Corey,D.R. (2010) Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. Chem. Biol., 17, 1183-1188.
34. Fiszer,A., Mykowska,A. and Krzyzosiak,W.J. (2011) Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats. Nucleic Acids Res., 39, 5578-5585.
35. Fiszer,A., Olejniczak,M., Galka-Marciniak,P., Mykowska,A. and Krzyzosiak,W.J. (2013) Self-duplexing CUG repeats selectively inhibit mutant huntingtin expression. Nucleic Acids Res., 41, 10426-10437.
36. Lee,J.M., Gillis,T., Mysore,J.S., Ramos,E.M., Myers,R.H., Hayden,M.R., Morrison,P.J., Nance,M., Ross,C.A., Margolis,R.L. et al. (2012) Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. Am. J. Hum. Genet., 90, 434-444.
37. van Bilsen,P.H., Jaspers,L., Lombardi,M.S., Odekerken,J.C., Burright,E.N. and Kaemmerer,W.F. (2008) Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum. Gene Ther., 19, 710-719.
38. Skotte,N.H., Southwell,A.L., Ostergaard,M.E., Carroll,J.B., Warby,S.C., Doty,C.N., Petoukhov,E., Vaid,K., Kordasiewicz,H., Watt,A.T. et al. (2014) Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. PLoS One, 9, e107434.
39. Carroll,J.B., Warby,S.C., Southwell,A.L., Doty,C.N., Greenlee,S., Skotte,N., Hung,G., Bennett,C.F., Freier,S.M. and Hayden,M.R. (2011) Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Mol. Ther., 19, 2178-2185.
40. Godinho,B.M.,Malhotra,M., O'Driscoll,C.M. and Cryan,J.F. (2015) Delivering a disease-modifying treatment for Huntington's disease. Drug Discov. Today, 20, 50-64.
41. Leavitt,B., Tabrizi,S., Kordasiewicz,H., Landwehrmeyer,B., Henry,S., Zanardi,T., Swayze,E., Norris,D., Smith,A., Lane,R. et al. (2016) Discovery and early clinical development of ISIS-HTTRx, the first HTT-lowering drug to be tested in patients with Huntington's Disease (PL01.002). Neurology, 86, http://www.neurology.org/content/86/16 Supplement/PL01.002.
42. Rodriguez-Lebron,E., Denovan-Wright,E.M., Nash,K., Lewin,A.S. and Mandel,R.J. (2005) Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol. Ther., 12, 618-633.
43. Aronin,N. and Moore,M. (2012) Hunting down huntingtin. N. Engl. J. Med., 367, 1753-1754.
44. Singh,S.K., Nielsen,P., Koshkin,A.A. and Wengel,J. (1998) LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition. Chem. Commun., 455-456.
45. Zaghloul,E.M., Madsen,A.S., Moreno,P.M., Oprea,L.L., El-Andaloussi,S., Bestas,B., Gupta,P., Pedersen,E.B., Lundin,K.E., Wengel,J. et al. (2011) Optimizing anti-gene oligonucleotide 'Zorro-LNA' for improved strand invasion into duplex DNA. Nucleic Acids Res., 39, 1142-1154.
46. Stein,C.A., Hansen,J.B., Lai,J., Wu,S., Voskresenskiy,A., Hog,A., Worm,J., Hedtjarn,M., Souleimanian,N., Miller,P. et al. (2010) Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res., 38, e3.
47. Madsen,A.S., Jorgensen,A.S., Jensen,T.B. and Wengel,J. (2012) Large scale synthesis of 2'-amino-LNA thymine and 5-methylcytosine nucleosides. J. Org. Chem., 77, 10718-10728.
48. Omi,K., Hachiya,N.S., Tokunaga,K. and Kaneko,K. (2005) siRNA-mediated inhibition of endogenous Huntington disease gene expression induces an aberrant configuration of the ER network in vitro. Biochem. Biophys. Res. Commun., 338, 1229-1235.
49. Kozlowski,P., de Mezer,M. and Krzyzosiak,W.J. (2010) Trinucleotide repeats in human genome and exome. Nucleic Acids Res., 38, 4027-4039.
50. Sobczak,K. and Krzyzosiak,W.J. (2005) CAG repeats containing CAA interruptions form branched hairpin structures in spinocerebellar ataxia type 2 transcripts. J. Biol. Chem., 280, 3898-3910.
51. Hanvey,J.C., Shimizu,M. and Wells,R.D. (1990) Site-specific inhibition of EcoRI restriction/modification enzymes by a DNA triple helix. Nucleic Acids Res., 18, 157-161.
52. Giovannangeli,C., Rougee,M., Garestier,T., Thuong,N.T. and Helene,C. (1992) Triple-helix formation by oligonucleotides containing the three bases thymine, cytosine, and guanine. Proc. Natl. Acad. Sci. U.S.A., 89, 8631-8635.
53. Consortium,E.P. (2012) An integrated encyclopedia of DNA elements in the human genome. Nature, 489, 57-74.
54. Komarnitsky,P., Cho,E.J. and Buratowski,S. (2000) Different phosphorylated forms of RNA polymerase II and associated mRNA processing factors during transcription. Genes Dev., 14, 2452-2460.
55. Ezzat,K., Andaloussi,S.E., Zaghloul,E.M., Lehto,T., Lindberg,S., Moreno,P.M., Viola,J.R., Magdy,T., Abdo,R., Guterstam,P. et al. (2011) PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res., 39, 5284-5298.
56. Simon,P., Cannata,F., Concordet,J.P. and Giovannangeli,C. (2008) Targeting DNA with triplex-forming oligonucleotides to modify gene sequence. Biochimie, 90, 1109-1116.
57. Lundin,K.E., Gissberg,O. and Smith,C.I. (2015) Oligonucleotide therapies: the past and the present. Hum. Gene Ther., 26, 475-485.
58. Lundin,K.E., Hojland,T., Hansen,B.R., Persson,R., Bramsen,J.B., Kjems,J., Koch,T., Wengel,J. and Smith,C.I. (2013) Biological activity and biotechnological aspects of locked nucleic acids. Adv. Genet., 82, 47-107.
59. Moreno,P.M., Geny,S., Pabon,Y.V., Bergquist,H., Zaghloul,E.M., Rocha,C.S., Oprea,L.L., Bestas,B., Andaloussi,S.E., Jorgensen,P.T. et al. (2013) Development of bis-locked nucleic acid (bisLNA) oligonucleotides for efficient invasion of supercoiled duplex DNA. Nucleic Acids Res., 41, 3257-3273.
60. Ge,R., Heinonen,J.E., Svahn,M.G.,Mohamed,A.J., Lundin,K.E. and Smith,C.I. (2007) Zorro locked nucleic acid induces sequence-specific gene silencing. FASEB J., 21, 1902-1914.
61. Ge,R., Svahn,M.G., Simonson,O.E.,Mohamed,A.J., Lundin,K.E. and Smith,C.I. (2008) Sequence-specific inhibition of RNA polymerase III-dependent transcription using Zorro locked nucleic acid (LNA). J. Gene Med., 10, 101-109.
62. Ling,J.Q., Hou,A. and Hoffman,A.R. (2011) Long-range DNA interactions are specifically altered by locked nucleic acid-targeting of a CTCF binding site. Biochim. Biophys. Acta, 1809, 24-33.
63. Beane,R.L., Ram,R., Gabillet,S., Arar,K., Monia,B.P. and Corey,D.R. (2007) Inhibiting gene expression with locked nucleic acids (LNAs) that target chromosomal DNA. Biochemistry, 46, 7572-7580.
64. Weidner,D.A., Valdez,B.C., Henning,D., Greenberg,S. and Busch,H. (1995) Phosphorothioate oligonucleotides bind in a non sequence-specific manner to the nucleolar protein C23/nucleolin. FEBS Lett., 366, 146-150.
65. Liang,X.H., Shen,W., Sun,H., Prakash,T.P. and Crooke,S.T. (2014) TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotide-induced nuclear bodies in mammalian cells. Nucleic Acids Res., 42, 7819-7832.
66. Liang,X.H., Sun,H., Shen,W. and Crooke,S.T. (2015) Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages. Nucleic Acids Res., 43, 2927-2945.
67. Kurreck,J., Wyszko,E., Gillen,C. and Erdmann,V.A. (2002) Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res., 30, 1911-1918.
68. Mirkin,S.M. (2007) Expandable DNA repeats and human disease. Nature, 447, 932-940.
69. Duzdevich,D., Li,J., Whang,J., Takahashi,H., Takeyasu,K., Dryden,D.T., Morton,A.J. and Edwardson,J.M. (2011) Unusual structures are present in DNA fragments containing super-long Huntingtin CAG repeats. PLoS One, 6, e17119.
70. Chung,D.W., Rudnicki,D.D., Yu,L. and Margolis,R.L. (2011) A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression. Hum. Mol. Genet., 20, 3467-3477.
71. Phatnani,H.P. and Greenleaf,A.L. (2006) Phosphorylation and functions of the RNA polymerase II CTD. Genes Dev., 20, 2922-2936.
72. Ezzat,K., Zaghloul,E.M., El Andaloussi,S., Lehto,T., El-Sayed,R., Magdy,T., Smith,C.I. and Langel,U. (2012) Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simulated gastric conditions. J. Control Release, 162, 1-8.
73. Soifer,H.S., Koch,T., Lai,J., Hansen,B., Hoeg,A., Oerum,H. and Stein,C.A. (2012) Silencing of gene expression by gymnotic delivery of antisense oligonucleotides. Methods Mol. Biol., 815, 333-346.
74. Torres,A.G., Threlfall,R.N. and Gait,M.J. (2011) Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2'-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents. Artif DNA PNA XNA, 2, 71-78.
75. Bestas,B., Moreno,P.M., Blomberg,K.E., Mohammad,D.K., Saleh,A.F., Sutlu,T., Nordin,J.Z., Guterstam,P., Gustafsson,M.O., Kharazi,S. et al. (2014) Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model. J. Clin. Invest., 124, 4067-4081.
76. Verhaart,I.E., van den Dool,L., Sipkens,J.A., de Kimpe,S.J., Kolfschoten,I.G., van Deutekom,J.C., Liefaard,L., Ridings,J.E., Hood,S.R. and Aartsma-Rus,A. (2014) The dynamics of compound, transcript, and protein effects after treatment with 2OMePS antisense oligonucleotides in mdx mice. Mol. Ther. Nucleic Acids, 3, e148.
77. Wengel,J., Petersen,M., Nielsen,K.E., Jensen,G.A., Hakansson,A.E., Kumar,R., Sorensen,M.D., Rajwanshi,V.K., Bryld,T. and Jacobsen,J.P. (2001) LNA (locked nucleic acid) and the diastereoisomeric alpha-L-LNA: conformational tuning and high-affinity recognition of DNA/RNA targets. Nucleosides Nucleotides Nucleic Acids, 20, 389-396.
78. Johannsen,M.W., Crispino,L., Wamberg,M.C., Kalra,N. and Wengel,J. (2011) Amino acids attached to 2'-amino-LNA: synthesis and excellent duplex stability. Org. Biomol. Chem., 9, 243-252.